Dopamine is the Primary Neurotransmitter Implicated in ADHD
Dopamine dysfunction, particularly involving the dopamine transporter (DAT) and dopamine receptors in the striatum and prefrontal cortex, represents the primary neurotransmitter abnormality in ADHD. 1
Core Dopaminergic Mechanisms
The evidence strongly supports dopamine as the central neurotransmitter system in ADHD pathophysiology:
Stimulant medications (methylphenidate and amphetamines) work primarily by binding to the dopamine transporter in the striatum, increasing synaptic dopamine levels, which enhances executive control processes in the prefrontal cortex. 1 This mechanism directly ameliorates the deficits in inhibitory control and working memory characteristic of ADHD.
The dopamine transporter gene (DAT1) is consistently associated with ADHD and affects striatal activation patterns in a manner that translates genetic risk into neurobiological substrate. 2 Genetic studies have identified multiple dopamine-related genes implicated in ADHD, including dopamine receptor genes (DRD4, DRD5, and DRD2). 3, 4
Patients with ADHD demonstrate depleted dopamine levels, thought to result primarily from dysfunction of the dopamine transporter system. 4 This depletion particularly affects frontal regions and associated subcortical structures that control attention and impulse regulation.
Norepinephrine as a Secondary but Important System
While dopamine is primary, norepinephrine plays a complementary role:
Norepinephrine dysfunction contributes to ADHD pathophysiology, with the norepinephrine system potentially dysregulated such that it fails to efficiently "prime" the cortical posterior attention system to external stimuli. 5 The dopamine beta-hydroxylase gene, which catalyzes conversion of dopamine to norepinephrine, is also associated with ADHD. 4
In brain regions expressing both DAT and the norepinephrine transporter (NET), the NET can clear dopamine as well as norepinephrine, creating overlapping effects. 6 This complicates distinguishing their relative contributions but underscores that both catecholamines work together.
Emerging Evidence for Serotonin
Recent high-quality evidence (2025) suggests serotonin may be more important than previously recognized:
Multiple recent systematic reviews found that 81.1% of identified studies provide support for altered serotonin production, binding, transport, or degradation in ADHD. 7 However, this evidence remains incomplete and at times conflicting compared to the robust dopamine literature.
Serotonin appears to have important neuromodulatory effects on the catecholaminergic system, particularly in mediating hyperactivity-impulsivity and emotional dysregulation symptoms. 8 This suggests serotonin dysfunction may be secondary to or interactive with primary dopaminergic abnormalities.
Clinical Implications
The dopaminergic mechanism explains why:
Stimulants remain the medications of choice for ADHD treatment, as they directly target the dopamine transporter and increase dopamine availability in critical brain regions. 1
PET scanning studies show that oral methylphenidate occupies a high proportion of dopamine transporter sites in the striatum, correlating with therapeutic response. 1
The efficacy of stimulant agents confirms that neurotransmitter abnormalities in ADHD are primarily catecholaminergic (dopamine and norepinephrine) in origin. 4
Important Caveat
A simple "too much" or "too little" hypothesis for any single neurotransmitter no longer suffices. 5 The pathophysiology involves complex interactions between dopamine, norepinephrine, and potentially serotonin systems, but dopamine dysfunction remains the primary and best-established mechanism underlying ADHD symptoms and treatment response.